Email this article Gene pharmacotherapy Inoperable patients with chronic lower limb ischemia
- Issue: Vol 19, No 4 (2011)
- Pages: 28-37
- Section: Articles
- URL: https://bakhtiniada.ru/pavlovj/article/view/4927
- DOI: https://doi.org/10.17816/PAVLOVJ2011428-37
- ID: 4927
Cite item
Full Text
Abstract
The article presents the results of the comparative six-month surveillance inoperable patients with atherosclerosis of lower extremities with clinical manifestations in the form of intermittent claudication (IIa-III century. AVPokrovskii to Fontaine), which are composed of conservative therapy received the drug genterapevtichesky "Neovaskulgen", a plasmid with the gene structure of vascular endothelial growth factor. The study included 50 patients (35 – in the clinical group and 15 – in the control group). The drug was administered intramuscularly, as close as possible to areas of ischemia, twice, at doses of 1.2 mg, with an interval of 14 days. Patients kontralirovlai: the length of pain-free walking distance, ankle-brachial index, transcutaneous oxygen napryazhdenie determined, the linear velocity of blood flow in the affected segment. It is established that in the clinical group were significantly increasing the length of pain-free walking distance, the linear velocity krovtoka. To a lesser extent the other indicators are growing. In the control group had deterioration of patients. The obtained results show the effectiveness of the drug "Neovaskulgen."
Full Text
##article.viewOnOriginalSite##References
- Мировой опыт генотерапии ишемических заболеваний / Р.В. Деев [и др.] // Ангиология и сосудистая хирургия. – 2011. – Т. 17, №2. – С. 145-154.
- Национальные рекомендации по ведению пациентов с сосудистой артериальной патологией (Российский согласительный документ). – М.: Изд-во НЦССХ им. А.Н. Бакулева РАМН, 2010. – Ч. 1. Периферические артерии.
- Клиническая ангиология: руководство для врачей / под ред. А.В. Покровского. – М., 2004. – Т. 1. – 808 с.
- Результаты 1/2а фазы клинических испытаний генотерапевтического препарата для терапевтического ангиогенеза / П.Г. Швальб [и др.] // Сердечно-сосудистые заболевания: бюл. НЦССХ им. А.Н. Бакулева РАМН. – 2010. – Т. 11, №6. – С. 262. – (Содерж. журн.: Тез. докл. 16-го Всерос. съезда сердечно-сосудистых хирургов (Москва, 28 ноября-1 декабря, 2010).
- Gupta R. Human Studies of Angiogenic Gene Therapy / R. Gupta, J. Tongers, D.W. Losordo // Circ. Res. – 2009. – Vol. 105. – P. 724-736.
- Vascular endothelial growth factor-induced angiogenic gene therapy in patients with peripheral artery disease, phase I-IIa and IIb-III study / R.E. Kalinin [et al.] // The European Society for Cardiovascular and Endovascular Surgery 60th International Congress (Mosсow, May 20-22, 2011) // Inter. Cardiovasc. Thoracic Surg. – 2011. – Vol. 12 (Suppl 1). – Р. 374.
- Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II) / L. Norgren [et al.] // Eur. J. Vasc. Endovasc. Surg. – 2007. – Vol. 33. – Р. 31-370.
Supplementary files
